[go: up one dir, main page]

US5889049A - Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators - Google Patents

Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators Download PDF

Info

Publication number
US5889049A
US5889049A US08/373,294 US37329495A US5889049A US 5889049 A US5889049 A US 5889049A US 37329495 A US37329495 A US 37329495A US 5889049 A US5889049 A US 5889049A
Authority
US
United States
Prior art keywords
method defined
inflammation
inflammatory
release
pharmaceutical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/373,294
Other languages
English (en)
Inventor
Uwe R. Juergens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4319554A external-priority patent/DE4319554C2/de
Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US5889049A publication Critical patent/US5889049A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the use of saturated monocyclic or bicyclic terpenes for the treatment of inflammatory diseases. It is particularly concerned with the use of saturated monocyclic terpenes for the treatment of steroid-requiring inflammatory diseases exacerbated by infection, such as, for example, bronchial asthma.
  • Acute and/or chronic inflammatory or acute allergic and/or chronic allergic inflammatory lesions are characterized by inflammatory infiltration of various organ systems by monocytes/macrophages, eosinophils, basophils and neutrophils, granulocytes, mast cells and thrombocytes.
  • the degree of inflammatory activity correlates with the influence of these inflammatory cells in organ tissue, which causes damage to the organ concerned.
  • These processes are a familiar feature in primary inflammatory diseases of the airways, the intestine and the articular cartilage in rheumatoid arthritis. Since the primary cause triggering most chronic inflammatory diseases is not known, these diseases can only be alleviated by nonspecific suppression of the inflammation stimulus. In an appropriate genetic predisposition or in the presence of environmental noxae, the reaction of the body to the exogenous noxae can be inhibited prophylactically by nonspecific suppression of the inflammation stimulus before the manifestation of disease symptoms.
  • the further migration of inflammatory cells into an area of inflammation can be reduced by inhibiting chemotactic factors.
  • immunosuppressants e.g. corticosteroids.
  • This group of agents is known to have an activity profile which comprises a strong anti-inflammatory effect, but is only poorly tolerated since it causes severe side effects, namely osteoporosis, gastric and duodenal ulcers, steroid purpura or lymphopenia.
  • Corticosteroids are known to inhibit the activity of phospholipase and cytokines in various inflammatory cells. After inhibition of the phospholipase activity, the release of arachidonic acid from the phospholipid stores in the cell membrane is inhibited. Arachidonic acid is known to be an important substrate for the formation of various mediators.
  • the actual inhibitory action on inflammation is mediated by inhibition of cytokine production and via a reduced production of arachidonic acid.
  • the latter is the precursor for the formation of potent chemotactic metabolites of the 5-lipoxygenase pathway (leukotrienes) and the cyclo-oxygenase pathway (prostaglandins, thromboxane) with a constrictor action on smooth muscle cells.
  • the need for systemically active corticosteroids is therefore reduced and the activity of the inflammatory process is suppressed with diminishing infiltration with inflammatory cells.
  • the subject matter of the present invention is the use of saturated monocyclic or bicyclic terpenes, especially those of a menthane, terpene alcohol, thiol, ketone or carane, pinane, bornane basic structure or a corresponding oxo compound of the bicyclic terpene structures (1,8-oxidomenthane and menthol are especially preferred) for suppression of the release of arachidonic acid, mediators of inflammation and cytokines.
  • FIG. 1 is a graph showing the effects of cineol on the FEV 1 in patients with asthma
  • FIG. 2 is a graph showing the effects of cineol on the airway resistance of patients with asthma
  • FIGS. 3 and 4 are graphs showing the effects of 1,8-cineol on LTB 4 production in patients with asthma in vivo;
  • FIG. 5 is a graph showing the inhibition of monocyte LTB 4 production in normal subjects and in asthma patients.
  • FIG. 6 is a graph showing the inhibition of AA metabolism in normal monocytes by 1,8-cineol.
  • the saturated, monocyclic and bicyclic terpene structures which can be used in accordance with the invention include inter alia monocyclic terpenes of the menthol type ((-)menthane-3-ol) and the eight stereoisomers as well as 1,8-terpin, menthone (p-menthane-3-one) as examples of terpene alcohols and terpene ketones as well as terpene thiols and the bicyclic terpenes.
  • terpene alcohols p-menthane-3-one
  • terpene ketones as well as terpene thiol
  • sarcoidosis fibrosis, exogenous allergic alveolitis, pneumoconioses, diseases of the efferent biliary tract, especially cholecystitis and cholangitis, diseases of the efferent urinary tract, especially glomerulonephritis, pyelonephritis, cystitis, urethritis as well as inflammatory and allergic skin diseases (especially eczema and psoriasis) and inflammatory arterial and venous vascular diseases including arteriitis, arteriosclerosis and phlebitis.
  • 1,8-cineol is suitable for treating inflammatory allergic and/or inflammatory bronchopulmonary diseases requiring steroid treatment and exacerbated by infection.
  • the group reduces the product of arachidonic acid. In this way, it suppresses arachidonic metabolism in the 5-lipoxygenase pathway.
  • an inhibition of interleukin 1 ⁇ (IL 1 - ⁇ ) was found.
  • Interleukin 1 ⁇ conditions human cells to release arachidonic acid and is known to be a strong proinflammation mediator itself. The effects may be attributed to its lipophilic properties, i.e. the diffusion and storage in fat tissue.
  • Cineol is the main constituent (about 80%) of the eucalyptus oils of the various kinds of Eucalyptus globulus type.
  • 1,8-Oxidomenthane is a bicyclic ether which has a tension-free ring system and is designated 2-oxa-bicyclo/2,2,2/-octane according to IUPAC. It is a colorless fluid, with an aromatic camphorlike smell which is also present in sage, myrtle, eucalyptol and other ethereal oils.
  • the dosage varies in the saturated monocyclic and bicyclic terpene structures, but is lower than the doses at which adverse side effects or indeed intoxications are manifested.
  • a dosage of 200 mg/day to 900 mg/day can be administered in the form of gastric juice-resistant capsules with a dose unit of 100 mg/capsule.
  • 1,8-cineol and menthol are suitable as additives for long-term intravenous infusion and for intramuscular administration. Cineol and menthol can be combined with other substances.
  • the dosage of menthol is between 100 mg/day and 450 mg/day.
  • 1,8-cineol is administered for the purposes of the invention at a dosage of 200 mg/day to 900 mg/day (by preference 600 mg/day).
  • the overall amount of the substances mentioned is appropriately divided into three doses per day.
  • the medical preparation forms can be solid or fluid.
  • Additives include fillers, dispersants, binding agents, moisteners, stabilizers, lubricants, emulsifiers, sweeteners, flavors and similar.
  • additives include for example Melantine solutions, pectin solutions, lactose, sodium chloride, talcum, starch, boric acid, paraffin oil, paraffin, stearic acid and its derivatives, cocoa butter, rubber, syrups, licorice extracts, yeast extracts, honey, glycerol, silicious earth, kaolin, magnesium oxide, beeswax and plant oils.
  • water, glycerol, sugar or alcohol solutions or mixtures of these can be used as vehicle and auxiliary agent.
  • the methods of optimizing the formulation are familiar to the specialist (Chemie in ken Zeit 23, 114 and 161 (1989)).
  • the tubes containing the cells were centrifuged for five minutes at 4° C. and the culture supernatants obtained were stored at -80° C. until further analysis. Afterwards, the culture supernatants were thawed and LTB 4 determined with a specific enzyme immunoassay.
  • FIG. 5 The LTB 4 production in monocytes of seven healthy test subjects (25 ⁇ 2 years) before and after the same cineol treatment was also used for comparison (see FIG. 5). Compared to patients with asthma, the LTB 4 production had also fallen in healthy patients, so that a general effect must be assumed.
  • FIG. 6 shows that cineol alone also inhibits the calcium ionophore A23187-stimulated LTB 4 production in monocytes. Consequently, cineol on its own is also suitable for treating inflammatory bronchopulmonary disease exacerbated by infections.
  • FIG. 5 show the unexpected synergistic efficacy of 1,8-cineol in the treatment of bronchial asthma patients in accordance with the invention, because even cortisone treatment could not reduce LTB 4 production to normal, whereas simultaneous cineol treatment brings LTB 4 production into the normal range, so that cortisone can be saved to an equal extent.
  • the corticosteroid requirement before cineol averaged 8.9 ⁇ 3.3 mg/day (range 0-24 mg) and could be reduced after 43.5 ⁇ 7.3 days to 4.0 ⁇ 1.3 mg/day (range 0-8 mg/day).
  • the reduction of steroid therapy did not have any negative effect on lung function.
  • the LTB 4 production for cineol had also fallen after long-term therapy.
  • results of long-term therapy show for the first time that there is a marked decrease in the daily steroid requirement under therapy with cineol without deterioration of lung function.
  • the average LTB 4 production under cineol after long-term therapy is markedly suppressed.
  • the reduction of systemic corticosteroids under long-term therapy with cineol only leads to a rise of the LTB 4 production in patients who as a result of a high steroid dose had shown suppression of LTB 4 production in vitro before cineol administration.
  • bronchial asthma In patients with bronchial asthma, an improvement of lung function could be attained as under cineol treatment after four days of therapy with the above dose. After long-term therapy for 12 weeks, the bronchial asthma stabilized to such an extent that the systemic corticosteroid requirement could be reduced by up to 50%. The treatment was tolerated well without side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
US08/373,294 1993-06-13 1994-06-11 Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators Expired - Fee Related US5889049A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4319556.3 1993-06-13
DE4319554.7 1993-06-13
DE4319554A DE4319554C2 (de) 1993-06-13 1993-06-13 Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
DE19934319556 DE4319556C2 (de) 1993-06-13 1993-06-13 Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (de) 1993-06-13 1994-06-11 Verwendung von terpenverbindungen zur verminderten freisetzung von arachidonsäure und entzündungsmediatoren

Publications (1)

Publication Number Publication Date
US5889049A true US5889049A (en) 1999-03-30

Family

ID=25926728

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/373,294 Expired - Fee Related US5889049A (en) 1993-06-13 1994-06-11 Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators

Country Status (19)

Country Link
US (1) US5889049A (sk)
EP (1) EP0654994B1 (sk)
JP (1) JPH08500612A (sk)
AT (1) ATE173622T1 (sk)
AU (1) AU680663B2 (sk)
BG (1) BG62474B1 (sk)
BR (1) BR9405404A (sk)
CA (1) CA2140660A1 (sk)
CZ (1) CZ285025B6 (sk)
DE (1) DE59407336D1 (sk)
DK (1) DK0654994T3 (sk)
ES (1) ES2126123T3 (sk)
HU (1) HUT69684A (sk)
NO (1) NO313814B1 (sk)
PL (1) PL308539A1 (sk)
RO (1) RO111989B1 (sk)
RU (1) RU2161482C2 (sk)
SK (1) SK282308B6 (sk)
WO (1) WO1994028895A2 (sk)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190671B1 (en) * 1992-07-20 2001-02-20 L'oreal Drug, particularly an immunomodulator, containing non-fructifying, non-photosynthetic filamentous bacteria envelopes or fractions thereof, and preparation thereof
US6420435B1 (en) 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6432937B1 (en) * 1996-12-20 2002-08-13 Astra Aktiebolag Treatment for joint inflammation
US20030199592A1 (en) * 2002-04-19 2003-10-23 Wilkins Joe S. Method for treating Crohn's Disease
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US6733794B1 (en) * 1999-12-17 2004-05-11 Edward L. Ingram Topical composition for antiseptic and analgesic purposes
US20060135585A1 (en) * 2002-10-31 2006-06-22 National Jewish Medical And Research Center Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20110257138A1 (en) * 2008-09-04 2011-10-20 Harold Greve Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
US20130281876A1 (en) * 2010-10-15 2013-10-24 Medimmune Limited Therapies for improving pulmonary function
US20160000722A1 (en) * 2010-05-12 2016-01-07 Harald Greve Dosage form for cineole

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2329583A (en) * 1997-09-25 1999-03-31 Marilyn Rydstrom Use of tea-tree oil for prophylaxis against cystitis
EP1071440B1 (en) 1998-04-16 2007-01-03 Eurovita A/S Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga
RU2210357C1 (ru) * 2002-04-26 2003-08-20 Леонова Наталия Сергеевна Ароматический лечебно-профилактический состав доктора леоновой н.с.
DE202010007074U1 (de) 2010-05-12 2011-08-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
RU2590979C2 (ru) * 2011-02-11 2016-07-10 ЗедЭкс ФАРМА, ЭлЭлСи Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
DE202012000910U1 (de) 2012-01-20 2013-01-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) * 2012-03-12 2012-07-12 Lotte Co Ltd 線毛運動活性化剤及びそれを含む飲食品

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
US4775667A (en) * 1985-09-26 1988-10-04 Shionogi & Co., Ltd. Topical analgesic anti-inflammatory composition
JPH0426619A (ja) * 1990-05-18 1992-01-29 Lotte Co Ltd 抗アレルギー剤および抗アレルギー剤を含有する食品添加物
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
DE4211745A1 (de) * 1992-04-03 1993-10-07 Boerner Gmbh Verwendung von Propolis und/oder seinen Fraktionen
US5294443A (en) * 1990-03-14 1994-03-15 Board Of Regents, The University Of Texas System Tripterygium wilford II hook f extracts and components thereof for immunosuppression
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US5338758A (en) * 1992-04-03 1994-08-16 Schering Corporation Bicyclic diterpene PAF antagonist compounds
US5420162A (en) * 1991-04-08 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Phorbol ester pharmaceutical compositions and their use for treating inflammation
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8602818A1 (es) * 1983-10-31 1985-12-01 Merck Frosst Canada Inc Una composicion farmaceutica

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
US4775667A (en) * 1985-09-26 1988-10-04 Shionogi & Co., Ltd. Topical analgesic anti-inflammatory composition
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5294443A (en) * 1990-03-14 1994-03-15 Board Of Regents, The University Of Texas System Tripterygium wilford II hook f extracts and components thereof for immunosuppression
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
JPH0426619A (ja) * 1990-05-18 1992-01-29 Lotte Co Ltd 抗アレルギー剤および抗アレルギー剤を含有する食品添加物
US5420162A (en) * 1991-04-08 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Phorbol ester pharmaceutical compositions and their use for treating inflammation
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US5338758A (en) * 1992-04-03 1994-08-16 Schering Corporation Bicyclic diterpene PAF antagonist compounds
DE4211745A1 (de) * 1992-04-03 1993-10-07 Boerner Gmbh Verwendung von Propolis und/oder seinen Fraktionen
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Associated with the Common Cold. J. Pharm. Pharmacol., vol. 42, pp. 652 654. (1990). *
Associated with the Common Cold. J. Pharm. Pharmacol., vol. 42, pp. 652-654. (1990).
Cousergue, J.L. Allergy to Terpene Products in Asthmatic Subjects (Occupational Allergies Excluded). Moroccan Study. Rev Fr Allergol. vol. 5, No. 3, pp. 160 168 (1965). Full Translation. *
Cousergue, J.L. Allergy to Terpene Products in Asthmatic Subjects (Occupational Allergies Excluded). Moroccan Study. Rev-Fr-Allergol. vol. 5, No. 3, pp. 160-168 (1965). Full Translation.
Cousergue, J.L., Allergies to Terpene Products in Asthmaties., Revue Francese D Allergolgie 5, 3 Jul. Sep. 1965, pp. 160 168 (Full Translated Copy). *
Cousergue, J.L., Allergies to Terpene Products in Asthmaties., Revue Francese D'Allergolgie 5, 3 Jul.-Sep. 1965, pp. 160-168 (Full Translated Copy).
Eccles, R., et al., The Effects of Oral Administration of ( ) Menthol on Nasal Resistance to Airflow & Nasal Sensation of Airflow in Subjects Suffering from Nasal Congestion. *
Eccles, R., et al., The Effects of Oral Administration of (-) Menthol on Nasal Resistance to Airflow & Nasal Sensation of Airflow in Subjects Suffering from Nasal Congestion.
Fawzy, A.A., et al. Inhibition Of Human Non Pancreatic Phospholipases A2 by Retinoids and Flavonoids. Mechanism of Action. Agents & Actions. 25(3 4) pp. 394 400. (1988). *
Fawzy, A.A., et al. Inhibition Of Human Non-Pancreatic Phospholipases A2 by Retinoids and Flavonoids. Mechanism of Action. Agents & Actions. 25(3-4) pp. 394-400. (1988).
Fiedler Nagy, C., et al. Comparative Study of Natural and Synthetic Retinoids as Inhibitors of Arachidonic Acid Release and Metabolism in Rat Peritoneal Macrophages. Dermatogica. *
Fiedler-Nagy, C., et al. Comparative Study of Natural and Synthetic Retinoids as Inhibitors of Arachidonic Acid Release and Metabolism in Rat Peritoneal Macrophages. Dermatogica.
Fisher, D.A. Exercise Induced Bronchoconstriction Related to Isotretinoin Therapy. J Am Acad Dermatol. vol. 13, No. 3, p. 524. Sep. 1985. *
Fisher, D.A. Exercise-Induced Bronchoconstriction Related to Isotretinoin Therapy. J-Am-Acad-Dermatol. vol. 13, No. 3, p. 524. Sep. 1985.
Flower, R.J., et al. Anti inflammatory Steroids Induce Biosynthesis of Phospholipase A2 Inhibitor Which Prevents Prostaglandin Generation. Nature, vol. 278, pp. 456 459. 29 Mar. 1979. *
Flower, R.J., et al. Anti-inflammatory Steroids Induce Biosynthesis of Phospholipase A2 Inhibitor Which Prevents Prostaglandin Generation. Nature, vol. 278, pp. 456-459. 29 Mar. 1979.
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwegserkrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306 4311. (1987). Full Translation. *
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwegserkrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306-4311. (1987). Full Translation.
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwergekrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306 4311. (1987). *
Grimm, H. Antiobstruktive Wirksamkeit von Cineol Bei Atemwergekrankungen. Therapiewoche, vol. 37, No. 45, pp. 4306-4311. (1987).
Hope et al. Retinoids Inhibit Phoapholipase A2 in Human Synovial Fluid and Arachidonic Acid Release From Rat Peritoneal Macrophages. Inflammation, 14(5), pp. 543 549. (1990). *
Hope et al. Retinoids Inhibit Phoapholipase A2 in Human Synovial Fluid and Arachidonic Acid Release From Rat Peritoneal Macrophages. Inflammation, 14(5), pp. 543-549. (1990).
Trampsch, K.M., et al. Novel Inhibitor of Phospholipase A2 With Topical Anti Inflammatory Activity. Biochemical and Biophysical Research Communications. 189(1) pp. 272 279. Nov. 1992. *
Trampsch, K.M., et al. Novel Inhibitor of Phospholipase A2 With Topical Anti-Inflammatory Activity. Biochemical and Biophysical Research Communications. 189(1) pp. 272-279. Nov. 1992.
Vol. 175: Supplement 1, pp. 81 92. (1987). *
Vol. 175: Supplement 1, pp. 81-92. (1987).
Wagner, H., et al. in Vitro Inhibition of Prostaglandin Biosynthesis by Essential Oils and Phenolic Compounds. Planta Medica. No. 3, pp. 184 187. 1986. Full Translation. *
Wagner, H., et al. in-Vitro Inhibition of Prostaglandin Biosynthesis by Essential Oils and Phenolic Compounds. Planta Medica. No. 3, pp. 184-187. 1986. Full Translation.

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190671B1 (en) * 1992-07-20 2001-02-20 L'oreal Drug, particularly an immunomodulator, containing non-fructifying, non-photosynthetic filamentous bacteria envelopes or fractions thereof, and preparation thereof
US6432937B1 (en) * 1996-12-20 2002-08-13 Astra Aktiebolag Treatment for joint inflammation
US6420435B1 (en) 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6733794B1 (en) * 1999-12-17 2004-05-11 Edward L. Ingram Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
US20030199592A1 (en) * 2002-04-19 2003-10-23 Wilkins Joe S. Method for treating Crohn's Disease
US20060135585A1 (en) * 2002-10-31 2006-06-22 National Jewish Medical And Research Center Compounds and methods for thiol-containing compound efflux and cancer treatment
US20060058245A1 (en) * 2002-10-31 2006-03-16 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7498047B2 (en) * 2002-10-31 2009-03-03 National Jewish Medical And Research Center Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20110257138A1 (en) * 2008-09-04 2011-10-20 Harold Greve Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases
US11135194B2 (en) 2008-09-04 2021-10-05 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenes for treating respiratory diseases, in particular bronchopulmonary diseases
US20160000722A1 (en) * 2010-05-12 2016-01-07 Harald Greve Dosage form for cineole
US20130281876A1 (en) * 2010-10-15 2013-10-24 Medimmune Limited Therapies for improving pulmonary function

Also Published As

Publication number Publication date
CZ285025B6 (cs) 1999-05-12
SK282308B6 (sk) 2002-01-07
WO1994028895A2 (de) 1994-12-22
NO313814B1 (no) 2002-12-09
HUT69684A (en) 1995-09-28
NO950518D0 (no) 1995-02-10
RO111989B1 (ro) 1997-04-30
BG99499A (bg) 1995-12-29
ATE173622T1 (de) 1998-12-15
BG62474B1 (bg) 1999-12-30
EP0654994A1 (de) 1995-05-31
AU680663B2 (en) 1997-08-07
CZ37095A3 (en) 1995-11-15
SK30395A3 (en) 1995-11-08
ES2126123T3 (es) 1999-03-16
CA2140660A1 (en) 1994-12-22
BR9405404A (pt) 1999-05-25
DE59407336D1 (de) 1999-01-07
NO950518L (no) 1995-02-10
HU9500714D0 (en) 1995-04-28
JPH08500612A (ja) 1996-01-23
PL308539A1 (en) 1995-08-21
DK0654994T3 (da) 1999-08-09
WO1994028895A3 (de) 1995-04-06
AU7000394A (en) 1995-01-03
RU2161482C2 (ru) 2001-01-10
EP0654994B1 (de) 1998-11-25

Similar Documents

Publication Publication Date Title
US5889049A (en) Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
Juergens et al. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1.8-cineole) in human blood monocytes in vitro
EP1174138B1 (en) Use of mometasone furoate for treating airway passage and lung diseases
US4743597A (en) Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4874603A (en) Use of vitamin E for normalization of blood coagulation during therapy with high unsaturated fatty acids of omega-3 type
EP2723344B1 (de) Monoterpenhaltiges kombinationstherapeutikum
JPH05213744A (ja) 炎症性疾患の処置のための薬剤調製物
US6432455B2 (en) Symptomatic relief of allergic reactions
DE69716341T2 (de) Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen
EP3911415A1 (en) Dapsone formulations and methods of using same
EP2830640B1 (en) Methods and compositions for treating arteriosclerotic vascular diseases
JPS60120812A (ja) 糖尿病性骨減少症治療剤
DE4319556C2 (de) Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
JP2522962B2 (ja) 乾癬治療剤
JP5952556B2 (ja) 褥瘡治療剤
EP3316882A1 (en) Thromboxane receptor antagonists in aerd/asthma
RU2153873C2 (ru) Применение кетоконазола и родственных веществ в лекарствах, предназначенных для лечения диабета типа ii
Ji et al. Clinical study on Danhong+ low-dose glucocorticoid treatment of severe pneumonia combined with myocardial injury.
Shindo et al. In VivoEffect of Prednisolone on Release of Leukotriene B4 from Neutrophils from Asthmatic Patients
AU2021249053A1 (en) Dapsone formulations and methods of using same
EP2123265B1 (en) Endipalene formulations in the treatment of psoriasis
DE202021105404U1 (de) Neues Therapiekonzept für die Behandlung von Corona-Infektionen, insbesondere COVID-19-Infektionen
McLaurin et al. Metabolic monitoring of neurosurgical patients
Scarpitta et al. Duovent Comparecí to Carbuterol in the Treatment of Bronchospasm
HK1135331B (en) Use of mometasone furoate for treating airway passage and lung diseases

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110330